Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update
Elisa Ruiz-Arabi, Julián Torre-Cisneros, Victoria Aguilera, Rodrigo Alonso, Marina Berenguer, Oriol Bestard, Marta Bodro, Sara Cantisán, Jordi Carratalà, Juan José Castón, Elisa Cordero, Carme Facundo, María Carmen Fariñas, Mirian Fernández-Alonso, Mario Fernández‐Ruiz, Jesús Fortün, María Dolores García‐Cosío Carmena, Sabina Herrera, David Iturbe‐Fernández, Óscar Len, Francisco López‐Medrano, María O. López‐Oliva, Ibai Los‐Arcos, María Ángeles Marcos, Pilar Martín‐Dávila, Vı́ctor Monforte, Patricia Muñóz, David Navarro, Aurora Páez-Vega, Ana Belén Pérez, Natalia Redondo, Rodríguez Álvarez R., Alberto Rodríguez‐Benot, Isabel Rodríguez‐Góncer, Rafael San-Juan, Javier Sánchez‐Céspedes, Maricela Valerio, J.M. Vaquero, Diego Viasus, Elisa Vidal, José María Aguado
Abstract
Cytomegalovirus (CMV) infection remains a significant challenge in solid organ transplantation (SOT). The last international consensus guidelines on the management of CMV in SOT were published in 2018, highlighting the need for revision to incorporate recent advances, notably in cell-mediated immunity monitoring, which could alter the current standard of care. A working group including members from the Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Society of Transplantation (SET), developed consensus-based recommendations for managing CMV infection in SOT recipients. Recommendations were classified based on evidence strength and quality using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. The final recommendations were endorsed through a consensus meeting and approved by the expert panel.